Amarin (AMRN) Delays Hiring Vascepa Sales Reps Until Early December
Tweet Send to a FriendGet Alerts AMRN Hot Sheet
Down)
Trade AMRN Now!
Amarin Corporation plc (Nasdaq: AMRN) previously guided that it would make a decision to hire prospective sales representatives as part of its continued Vascepa commercialization preparations before the end of November 2012.
Amarin now expects to make this decision in the first half of December 2012 and continues to anticipate the launch of Vascepa early in the first quarter of 2013.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Amarin now expects to make this decision in the first half of December 2012 and continues to anticipate the launch of Vascepa early in the first quarter of 2013.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Oncolytics Biotech (ONCY) REOLYSIN w/ REO 020 Met Primary Endpoint in Phase 2
- Amarin's (AMRN) Vascepa Not in FDA Orange Book for April
- Sanofi (SNY), Regeneron (REGN) Report Publication of Positive Dupilumab Phase 2a Data
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
